Halozyme Therapeutics, Inc. (HALO) Posts Surprise Q2 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $131.18 --0%
EPS Growth %: +32.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
EPS Growth %: +32.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of $0.03, $0.16 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $4.95 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regal-Beloit (RBC) Tops Q3 EPS by 21c ; Offers Guidance
- Forum Energy Technologies (FET) Tops Q3 EPS by 29c ; Offers Guidance
- Magna International (MGA) Tops Q3 EPS by 25c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
